INTRODUCTION
============

It is estimated that 3% of the world\'s population is infected with hepatitis C virus (HCV), representing about 170 million people chronically infected and at risk of developing complications resulting from the infection[@B01].

We are currently experiencing the era of direct-acting antiviral drugs (DAAs), such as protease inhibitors (PI) that, when added to pegylated interferon (PEG-IFN) and ribavirin (RBV), are capable of achieving significant gains regarding sustained virological response (SVR). On the other hand, the use of these new molecules, despite their advantages, presents new challenges: the appearance of variants with a possible decreased sensitivity to new DAAs, a higher occurrence of adverse effects, drugs interactions, and a significant increase in the total cost of antiviral therapy[@B02]. The biggest obstacles to the success of treatment with the current triple therapy (first-generation PI) were the frequent, and sometimes severe, adverse effects. Thus, although a discussion about the adverse effects and mortality of dual therapy may seem unfruitful in the PI-era, we understand that it is still relevant, since at the present time some available drugs might be used in combination with PEG-IFN and RBV. It is worth noting that interferon-free therapies are not yet part of our reality.

This study aimed to evaluate the occurrence of adverse effects and mortality in cirrhotic patients due to hepatitis C, treated with PEG-IFN and RBV.

METHODS
=======

A descriptive, cross-sectional study was performed, in which we analyzed the medical records of all the patients with cirrhosis due to chronic hepatitis C who underwent treatment with dual therapy (PEG-IFN and RBV). The drugs used were PEG-IFN alpha-2a 180 mcg or PEG-IFN alpha-2b 1,5 mcg/kg, subcutaneously, once a week associated with RBV 15 mg/kg/day, orally. Patients were monitored by the Administration and Monitoring Center for Injectable Medications (CAMMI) at the *Hospital Nossa Senhora da Conceição* in *Porto Alegre*, a tertiary-care public hospital in Southern Brazil, in the period between March 2003 and June 2013.

Among the medical records, only the patients with cirrhosis were selected for analysis. The diagnosis of cirrhosis was defined by clinical, laboratory and/or image evidence, or by liver biopsy when necessary. Patients who were co-infected with the human immunodeficiency virus (HIV) and hepatitis B virus (HBV) were excluded.

We assessed each patient\'s demographic and clinical characteristics (age, gender, weight, previous treatment) as well as pre-treatment laboratorial/ biochemical parameters (hemoglobin levels, white blood cell count, platelet count, prothrombin time, total bilirubin, albumin, and serum creatinine). We also determined the patients\' HCV genotype and viral load. Additionally, the Child-Pugh-Turcotte[@B03] score and the MELD score - Model for End Stage Liver Disease[@B04]were considered, as well as the presence of esophageal varices.

To evaluate the virological response to treatment, we considered as non-responders (NR), patients who did not have a decrease of at least 2 logarithms in the HCV viral load at week 12 of treatment, or who had a detectable viral load at weeks 24 or 48 of treatment. Sustained virological response (SVR) was defined as the maintenance of a non-detectable HCV-RNA, assessed at week 24 of the follow-up, after the completion of treatment.

The early discontinuation of treatment was considered in all non-responders at week 12 of therapy, as well as in those who interrupted treatment due to serious adverse effects (SAE).

In the assessment of the safety profile of the therapy, we evaluated the reasons for treatment interruption, the need of drug dosage reduction, the occurrence of adverse events, and death.

The SAE were: decompensation of the liver disease, presence of severe infection during treatment, relevant anemia, neutropenia or thrombocytopenia despite reductions in drug dosages and use of erythropoietin (EPO) and/ or filgrastim. Anemia was considered when hemoglobin levels were equal to or below 10 g/dL, or hemoglobina decreased more than 3 g/dL compared to pre-tratament [@B05]. Neutropenia[@B06] was considered when the neutrophil count was equal to or less than 750 cells/mm^3^. Three levels of thrombocytopenia were considered: 150,000 to 100,000/mm^3^; 99,000 to 51,000/mm^3^ and equal to or less than 50,000/mm^3^.

Quantitative data was described as mean, standard deviation, and minimum and maximum values. Categorical data was presented as the total count and percentage. To obtain estimates for the association of selected factors with SVR we used the Odds Ratio (OR) calculated in a logistic regression model. Additionally, in the logistic regression model, a stepwise forward selection was performed to identify the variables that stood out in predicting SVR (all described in [Table 2](#t02){ref-type="table"} and [4](#t04){ref-type="table"}), according to the classical variables related to SVR and death described in the literature[@B07] ^,^ [@B08]. Additionally, a Cox proportional hazard model was designed to obtain hazard ratio estimates (HR) and their respective confidence intervals (CI). The significance level was set at a = 0.05. Data were analyzed using SPSS, version 22.

Table 1**-** Evaluated data in cirrhotic patients who underwent therapy with PEG-IFN and RBV**VariablesPatients**Male gender, n (%)143 (55.6)Age, years53.8±9.3Initial Weight, Kg75.7 ± 14.6Previous treatment, n (%)96 (37.4)Hemoglobin, g/dL14.1 ± 1.7Leukocytes, count/mm^3^5,394 ± 2,035Platelets, count/mm^3^120,421 ± 60,140Prothrombin time, s14.4 ± 3.7Total bilirubin, mg/dL1.11 ± 0.68Albumin, g/dL3.93 ± 0.60Creatinine, g/dL0.8 ± 0.2Child Pugh, n (%)A242 (89.4)B15 (10.6)MELD9.25 ± 3.1Esophageal varices, n (%)68 (27.8)Genotype n (%) (n=239)1153 (64.0)207 (2.9)379 (33.1)Viral load ≥ 600,000 IU/mL166 (65.1)[^1]

Table 2**-** Variables associated with SVR in patients with cirrhosis undergoing therapy with PEG-IFN and RBV**SVR (%) n = 45NR (%) n = 212ORCI95%*p***Male gender55.655.71.000.52-1.90\>0.99Age ≥ 6517.813.21.420.60-3.360.47Weight, Kg\*76.0^§^75.0^§^0.990.97-1.010.47Previous treatment51.134.41.991.04-3.810.42Hemoglobin ≥ 10 g/dL100.097.6\--0.59Leukocytes, count/mm^3^\*5,000^§^5,006^§^1.001.00-1.000.52Platelets ≥ 100,000/mm^3^63.450.71.680.84-3.360.17Prothrombin time \< 14s63.748.51.890.89-4.000.10Total Bilirubin ≥ 1mg/dL44.749.40.820.49-1.670.72Albumin ≥ 3.5 g/dL88.981.41.830.60-5.570.33Child B7.411.40.620.13-2.930.73MELD9.08.01.030.89-1.190.69Esophageal varices33.326.51.380.69-2.770.36Genotype (n=239)153.566.3-27.02.04.240.89-20.200.07339.531.61.550.77-3.110.22Viral Load \< 600,000 IU/mL60.029.53.711.85-7.14**\<0.001**[^2]

Table 3- Safety profile of therapy with PEG-IFN and RBVEventsPatients, n= 257Death11 (4.3)Discontinuation of treatment105 (40.8)Without early virological response60 (23.3)Adverse events39 (15.2)Other reasons: abandonment06 (2.3)PEG IFN Dosage Reduction54 (21.6)RBV Dosage Reduction66 (25.7)Anemia:Hb \< 10 g/dL or decrease of \> 3 g/dL192 (75)Use of erythropoietin22 (8.6)Neutrophils \< 750/ mm^3^50 (19.5)Use of filgrastim29 (11.3)Platelets150,000 to 100,000/ mm^3^72 (28)99,000 to 51,000/mm^3^125 (49)≤ 50,000 / mm^3^41 (16)[^3]

Table 4- Variables associated with death in patients who underwent dual HCV therapy**Death (%) n = 11Survival (%) n = 246HRCI95%*p***Male gender45.556.10.630.19-2.070.45Age ≥ 659.114.20.650.08-5.080.68Weight, Kg\*70.575.51.010.97-1.050.81Previous treatment27.337.80.581.15-2.180.49Hemoglobin ≥ 10 g/dL90.998.30.250.03-1.940.19Leukocytes \<4,000/mm^3^63.625.15.251.54-17.960.008Platelets ≥ 100,000/mm^3^40.053.40.570.16-2.020.39Prothrombin time ≥ 14s60.048.21.680.47-5.920.42Total Bilirubin ≥ 1mg/dL90.046.510.901.38- 86.080.024Albumin ≤ 3.5 g/dL60.015.09.092.56 -33.330.001Creatinine0.80.81.540.43-5.440.51Child B54.56.915.924.80-52.75\<0.001MELD12.58.01.261.08-1.480.003Esophageal varices30.027.71.020.26-3.930.98Genotype (n=239)160.064.2-20.03.1-340.032.81.270.3-4.520.71VL ≥ 600,000 IU/mL36.466.40.320.09-1.080.065[^4]

RESULTS
=======

The records of 1,059 patients with chronic liver disease due to HCV were evaluated. Of these, 776 patients without cirrhosis and 26 patients co-infected with HIV were excluded.

The demographic and clinical characteristics of the 257 cirrhotic patients, as well as the laboratory tests results and HCV-related data are shown in [Table 1](#t01){ref-type="table"}.

In assessing the response to the treatment used, 45 (17.5%) patients had SVR. The variables evaluated for the virological response are shown in [Table 2](#t02){ref-type="table"}. In the univariate analysis, the only variable considered significant for virological response was a viral load \< 600,000 IU/mL (OR: 3.71; CI:1.85-7.14; *p* \< 0.001). When the multivariate analysis was performed, a viral load \< 600,000 IU/mL (OR: 5.55; CI:2.00-16.66; *p* = 0.001) and a prothrombin time of less than 14 seconds (OR: 3.12; CI:1.07-9.09; *p* = 0.003) were considered significant.

The interruption of treatment occurred in 105 (40.8%) patients, of whom 60 (23.3%) did not show any virological response at week 12 of treatment, in 39 (15.2%) patients due to the appearance of adverse effects, and in six (2.3%) patients because they voluntarily requested to interrupt the treatment. Fifty-four (21.6%) patients required a lower dosage of PEG-IFN, and 66 (25.7%) patients had the RBV dosage reduced due to adverse effects. Among the adverse effects, anemia, neutropenia and thrombocytopenia (\< 100,000/mm^3^) stood out, affecting 75%, 19.5% and 65% of patients, respectively. Regarding the 11 (4.3%) deaths, five occurred as a result of hepatic decompensation, four due to infection, one due to upper gastrointestinal bleeding (rupture of esophageal varices), and one due to a stroke. [Table 3](#t03){ref-type="table"} illustrates the safety profile of therapy with PEG-IFN and RBV.

It should be highlighted that of the 11 deaths, six occurred in patients classified as Child-A (06/242; 2.4%) and five in patients classified as Child-B (05/15; 33.3%) (*p* \< 0.001).

When factors associated with mortality were evaluated in patients who underwent therapy with PEG-IFN and RBV, the variables that reached significance were ([Table 4](#t04){ref-type="table"}): liver failure represented by patients classified as Child B (HR: 15.92; CI: 4.80-52.75, *p*: \< 0.001); patients with high scores on the MELD scoring system (HR:1.26; CI:1.08-1.48, *p*: 0.003); albumin dosage lower than 3.5 g/dL (HR: 9.09; CI: 2.56-33.33, *p*: 0.001); total bilirubin ≥ 1 mg/dL (HR: 10.90; CI: 1.38-86.08; *p*: 0.024) and leukocyte count lower than 4,000 cells/mm^3^ (HR: 5.25; CI: 1.54-17.96; *p*: 0.008). It was not possible to perform the multivariate analysis because of the small number of deaths.

The median follow-up time was 48 weeks. When analyzing the patients\' survival in relation to the treatment time, the survival rate at the end of 48 weeks of treatment was 94.4%.

DISCUSSION
==========

The treatment of chronic hepatitis C has been rapidly evolving since the advent of new first-generation DAAs such as Telaprevir and Boceprevir [@B09] ^,^ [@B10] ^,^ [@B11] ^,^ [@B12] ^,^ [@B13]. A new generation of DAAs has already been approved for use in the United States and Europe[@B14] ^,^ [@B15]; however, it is not yet available in Latin America. Added to the fact that treatments using the new DAAs will, at times, also use PEG-IFN+RBV, the high mortality observed in cirrhotic patients with the use of PEG-IFN and RBV in this study is relevant.

A recent French study[@B07]that evaluated the treatment of cirrhotic patients with triple therapy (PEG-IFN+RBV+PI) showed that treatment with Telaprevir and Boceprevir presents a lower rate of SVR and low tolerance. Moreover, it showed a significant number of patients with adverse effects, sepsis, and higher mortality rates when compared to the register clinical trials[@B09] ^,^ [@B13], finding that triple therapy should be instituted with caution in this hard-to-treat population[@B16] ^,^ [@B17].

It must be highlighted that although this publication has been the one that alerted the medical community to the risks of HCV therapy, other studies had already called attention to the mortality associated to the dual therapy with PEG-IFN and RBV. However, not all studies assessing cirrhotic patients treated with dual therapy with PEG-IFN and RBV have mentioned mortality during treatment[@B08] ^,^ [@B18] ^,^ [@B19] ^,^ [@B20] ^,^ [@B21] ^,^ [@B22]although the occurrence of serious adverse effects has been described in up to 40% of cases[@B16] ^,^ [@B19] ^,^ [@B20] ^,^ [@B21] ^,^ [@B23] ^,^ [@B24].

Considering that patients selected for clinical trials constitute a subgroup of motivated individuals with fewer comorbidities, which is a better profile than that of patients treated in daily medical practice, it is not surprising that treatment results are often unable to reproduce the successful rates obtained in clinical trials[@B25] ^,^ [@B26].

In the present study, the efficacy of the studied treatment showed SVR in only 17.5% of patients. In the multivariate analysis, a viral load of less than 600,000 IU/mL and a prothrombin time of less than 14 seconds reached significance regarding SVR.

When 323 patients with chronic liver disease due to genotype 1 HCV treated with PEG-IFN and RBV were assessed, we observed a SVR of 35.3%, and 18.9% in patients with cirrhosis[@B27]. More recently, a large multicentric study [@B28] with 4,520 genotype 1 patients also observed a lower SVR compared to the register studies, with 32.4% in those with F3-F4 evaluated jointly. It is worth noting that, in general, in studies evaluating the treatment efficacy, the population of cirrhotic patients only represents a portion of the patients undergoing treatment[@B16] ^,^ [@B17] ^,^ [@B19] ^,^ [@B22] *.* The literature has been showing that the higher the degree of fibrosis, the lower the SVR[@B19] ^,^ [@B27] ^,^ [@B29] ^,^ [@B30].

In Fernandez-Rodriguez-APREVIR\'s[@B31] study carried out in a population of cirrhotic patients, a SVR of 30.7% was found. The independent variables associated with SVR were non-1 genotype, more than 80% of the planned duration of treatment, high serum level of gamma-glutamyl transpeptidase (GGT), viral load lower than 600,000 IU/mL, and no signs of portal hypertension on ultrasound.

In the study by Silva *et al*.[@B32], the authors have also included patients with F3 (METAVIR classification), and observed a SVR of 25%. The independent factors associated with SVR were HCV genotype 3, rapid virological response and lower Child score.

In general, studies evaluating SVR in patients with cirrhosis, despite showing a reduced response to therapy, also include patients with advanced fibrosis, without cirrhosis[@B16]. It is important to highlight that in the present study all the patients had cirrhosis, which explains the lower SVR.

In a systematic review that included 45 studies with chronic hepatitis C (cirrhotic and non-cirrhotic) patients, the SVR obtained in patients with compensated cirrhosis associated to HCV genotype 1 varied between 10 to 44%, and in those with genotype 2 or 3 between 33 to 72%. Rapid virological response was considered the most important predictive factor[@B30].

In the present study, 40% of patients had primary treatment discontinuation due to the absence of virological response at week 12 of treatment (23.3%), to adverse effects (15.2%) or to patients\' voluntary request for discontinuation of treatment (2.3%). Reduction of PEG-IFN dosage was necessary in 21.6% of participants, and reduction of the RBV dosage occurred in 25.7% of cases. Although serious adverse events and hematological changes were frequent, the high mortality rate observed (4.3%) has called our attention. However, it is noteworthy that this rate was of 2.4% when only Child A patients were considered. In classical international studies[@B33], the discontinuation of treatment due to adverse events occurred in 9 to 14%. Feuerstadt *et al*.[@B34] showed a discontinuation rate of 23%. In two studies performed with cirrhotic patients[@B21] ^,^ [@B24], discontinuation of therapy due to adverse events occurred in 16% and 29.6%, respectively. However, there are studies[@B19] ^,^ [@B21] that showed no significant differences of adverse effects in patients with and without cirrhosis.

SAE leading to discontinuation of treatment were observed in 15.2% of cases in the present study, whereas in the literature, SAE have been described in up to 40% of patients with compensated cirrhosis[@B16] ^,^ [@B18] ^,^ [@B19] ^,^ [@B20] ^,^ [@B21] ^,^ [@B24].

The mortality described in some studies that jointly assessed patients with F3 and F4 treated with PEG-IFN and RBV varied between 0.3% and 1.6%[@B17] ^,^ [@B28]. However, such studies present the data related to general mortality, without categorization of mortality according to the degree of fibrosis (F3 or F4).

It has already been demonstrated that serious complications are associated with the treatment in patients with decompensated cirrhosis or Child-Pugh B-C in up to 68%[@B08] ^,^ [@B24] ^,^ [@B35] ^,^ [@B36] ^,^ [@B37] ^,^ [@B38] ^,^ [@B39] and mortality in up to 7.6% of patients[@B08] ^,^ [@B37]. In the present study, despite the small number of treated patients, the observed mortality among Child B patients was 33.3%, emphasizing that poor performance during treatment is related to the severity of the liver disease (class B of Child score and increase in MELD score), a serum albumin level of less than 3.5 g/dL, a total bilirubin level higher than 1 mg/dL and a leukocyte count lower than 4,000 cells/mm^3^. In the studies that assessed mortality, some did not evaluate related factors[@B16] ^,^ [@B17] ^,^ [@B37], while the Child-C score and neutrophil count below 900/mm^3^ were independent predictive factors in the study by Iacobellis *et al*.[@B08]On the other hand, some classical variables related to prognosis as creatinine and protrombin time were not statistically significant, possibly due to the small number of deaths.

In conclusion, although the treatment provides an opportunity to eradicate HCV infection in patients with cirrhosis, thus preventing further progression of the disease[@B40] ^,^ [@B41], it can also cause serious adverse events and mortality. When treating this population, a careful evaluation of cirrhotic patients before treatment and a rigorous monitoring of serious adverse events during treatment are indicated. Therefore, whilst the therapy with new DAAs is not fully established, it is important that clinicians pay attention to the adverse effects of therapy with PEG-IFN and RBV.

[^1]: Data are presented as mean ± standard deviation or total count (percentage). HCV: hepatitis C virus, MELD: Model for Endstage Liver Disease

[^2]: CI: confidence interval; SVR: sustained virological response; NR: non-responders; \*odds ratio expressed by unit increase; §: median.

[^3]: Data presented in total numbers and percentage (%). PEG IFN: pegylated interferon, RBV: ribavirin, Hb: hemoglobin.

[^4]: CI: confidence interval; VL: viral load; \*:HR expressed by unit increase
